Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – Good Night, Good Hockey

Stem Cell Therapy Marketis expected to reach 202.77 billion by 2026 from XX billion in 2018 at CAGR of XX %. REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/522

Stands for use of stem cells to treat or prevent disease or condition.Bone marrow transplant and some therapies derived from umbilical cord blood are mainly used in stem cell therapy. Advancement, in order to establish new sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions, are increased in recent years.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Stem Cell Therapy Market Researchers are making efforts to discover novel methods to create human stem cells. This will increase the demand as well as supply for stem cell production and potential investigation in disease management. Increasing investment & research grants for developing safe and effective stem cell therapy products, the growing patient base for target diseases, concentrated product pipelines, increasing approval of the new clinical trials, rapid technological advancement in genomics, and the rising awareness about the stem cell are expected to drive the growth of the Stem Cell Therapy solutions market during the forecast period.

However, improper infrastructure, insufficient storage systems, nascent technology in underdeveloped economies, Ethical issues related to an embryonic stem cell, low patient acceptance rate, Difficulty in the preservation of stem cell are expected to restrain the market growth. North America is expected to be the largest growing region by 2026; the reason behind that is extensive funding by Government. However, Emerging countries like India, china, Korea have low growth rate as compared to Developed regions in 2017 but increase in awareness about stem cell therapy will lead the Asia Pacific to generate a significant level of revenue by 2026.

Key Highlights of Stem Cell Therapy Market report

Detailed quantitative analysis of the current and future trends from 2017 to 2026, which helps to identify the prevailing market opportunities. Comprehensive analysis of factors instrumental in changing the market scenario, rising prospective opportunities, market shares, core competencies in terms of market development, growth strategies and identification of key companies that can influence this market on a global and regional scale. Assessment of Market definition along with the identification of key drivers, restraints opportunities and challenges for this market during the forecast period. Complete analysis of micro-markets with respect to individual growth trends, prospects, and contributions to the overall Stem Cell Therapy Solutions market. Stem Cell Therapy market analysis and comprehensive segmentation with respect to the Application, End users, Treatment, and geography to assist in strategic business planning. Stem Cell Therapy market analysis and forecast for five major geographies-North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions. For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a global market value for the stem cell therapy market. Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are: Gamida Cell ReNeuron Group, plc Osiris Therapeutics, Inc. Stem Cells, Inc. Vericel Corporation. Mesoblast, Ltd.

Key Target Audience:

Stem Cell Associations and Organizations Government Research Boards and Organizations Research and consulting firms Stem Cell Therapy Market Investors Healthcare Service Providers (including Hospitals and Diagnostic Centers) Stem Cell Therapeutic Product Manufacturing Organizations Research Labs Clinical research organizations (CROs) Stem Cell Therapy Marketing Players Pharmaceutical Product Manufacturing Companies Scope of the Stem Cell Therapy Market Report:

Stem Cell Therapy market research report categorizes the Stem Cell Therapy market based on Application, End users, Treatment, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Stem Cell Therapy market with key developments in companies and market trends. Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

Hospitals Ambulatory Surgical Centers

Stem Cell Therapy Market, By Application:

Oncology Central Nervous System Diseases Eye Diseases Musculoskeletal Diseases Wound & Injuries Metabolic Disorders Cardiovascular Disorders Immune System Disorders Stem Cell Therapy Market, By Geography:

North America Europe Asia Pacific Middle East & Africa Latin America

Available Customization:

With the given market data, Maximize Market Research offers customization of report and scope of the report as per the requirement

Regional Analysis:

Breakdown of the North America stem cell therapy market Breakdown of the Europe stem cell therapy market Breakdown of the Asia Pacific stem cell therapy market Breakdown of the Middle East & Africa stem cell therapy market Breakdown of the Latin America stem cell therapy market

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read the original here:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Good Night, Good Hockey

Israel and UAE team up on stem cell therapy research for COVID-19 – UPI News

David Adom wears protective clothing while working in a coronavirus drive through tent in Jerusalem. On Monday, Israel and United Arab Emirates stem cell companies announced collaboration on research on COVID-19 treatments. Photo by Debbie Hill/UPI | License Photo

Aug. 17 (UPI) -- Israel and United Arab Emirates stem cell therapy companies signed an agreement Monday to collaborate on researching potential treatment for COVID-19.

The accord between Israel's Pluristem Therapeutics and UAE's Abu Dhabi Stem Cells Center aims to capitalize on each company's expertise to develop therapies and regenerative medicines for the treatment of severe diseases including COVID-19, according to a joint statement.

Both companies have been treating COVID-19 patients with stem cells.

Pluristem has been treating COVID-19 patients with a placenta-based stem cell therapy. The U.S. Food and Drug Administration cleared the Israel stem cell therapy company in May for a Phase II study of the treatment for severe COVID-19 cases. Preliminary results released in May from compassionate-use programs in Israel and the United States were promising, showing that 75 percent of participants no longer needed mechanical ventilation within 28 days.

The Abu Dhabi Stem Cells Center has started a therapy that returns blood-based stem cells back into the patient's lungs as a fine mist through a nebulizer.

"We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders," Pluristem CEO and President Yaky Yanay said in the statement.

The ADSCC's General Manager Dr. Yendry Ventura also commented on the deal in the statement.

"Pluristem is a major player in the cell therapy field with years of experience, a unique platform and robust clinical pipeline," Ventura said. "We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole."

The deal is the second cross-border agreement since President Donald Trump brokered a deal to normalize ties between Israel and the UAE. It follows a cross-border deal on Sunday between UAE-based APEX National Investment and Israel's TeraGroup to conduct research on the coronavirus.

World News // 21 minutes ago

South Korea official proposes changes to U.S. working group

Aug. 18 (UPI) -- South Korea's newly appointed unification chief proposed "readjustments" to a bilateral working-level group with the United States, during a meeting with the top U.S. envoy in Seoul.

World News // 3 hours ago

6.6-magnitude earthquake strikes Philippines; 1 dead

Aug. 18 (UPI) -- A 6.6-magnitude earthquake struck central Philippines Tuesday, killing at least one person, officials said.

World News // 14 hours ago

Toronto police agree to $12.5M settlement for mass arrests at G-20

Aug. 17 (UPI) -- Ten years after mass-arrests in Toronto at the 2010 G-20 economic summit, the Toronto Police Services Board will pay a $12.5 million settlement to members of a class-action lawsuit of 1,100 people who were detained.

World News // 19 hours ago

Spanish Royal Household confirms former king Juan Carlos I is in UAE

Aug. 17 (UPI) -- Spain's Royal Household confirmed Monday that emeritus king, Juan Carlos I, is in United Arab Emirates after uncertainty since he went into exile two weeks ago amid financial scandals.

World News // 19 hours ago

China has new weapon to target airfields, state media says

Aug. 17 (UPI) -- Beijing's military has developed a hybrid weapon capable of destroying an entire airfield with one hit, according to Chinese state media on Monday.

World News // 20 hours ago

South Korea police to handle spy cases, report says

Aug. 17 (UPI) -- Seoul's National Police Agency will take control over all investigations into anti-state espionage previously conducted by the National Intelligence Service.

World News // 22 hours ago

BTS music label worth $2.5B ahead of IPO, report says

Aug. 17 (UPI) -- The South Korean label that manages boy band BTS is expected to make an initial public offering after passing a preliminary screening, according to a South Korean press report.

World News // 22 hours ago

Ryanair cuts capacity for next 2 months due to restrictions

Aug. 17 (UPI) -- Irish carrier Ryanair announced Monday it will reduce flight capacity by 20% in September and October, due to European travel restrictions.

World News // 23 hours ago

North Korea quiet as U.S., South Korea exercises to resume

Aug. 17 (UPI) -- North Korea is keeping silent ahead of U.S.-South Korea military exercises this week.

World News // 23 hours ago

German regulators investigate Amazon pricing policies

Aug. 17 (UPI) -- Antitrust regulators in Germany are investigating complaints that Amazon is unfairly leveraging its dominant position in the e-commerce market to affect pricing during the coronavirus pandemic.

Excerpt from:
Israel and UAE team up on stem cell therapy research for COVID-19 - UPI News

Canine Stem Cell Therapy Market to Witness Stunning Growth to Generate Massive Revenue During Forecast 2020 2026 | VETSTEM BIOPHARMA, Cell Therapy…

Canine Stem Cell Therapy Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

The global Canine Stem Cell Therapy Market size is expected to Expand at Significant CAGR of +4% during forecast period (2020-2026).

The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=21262

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Vendors of this Market are:

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Canine Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Canine Stem Cell Therapy markets trajectory between forecast periods.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Canine Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Canine Stem Cell Therapy market.

Get Up to 20% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=21262

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Canine Stem Cell Therapy market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Global Canine Stem Cell Therapy Market Segmentation:

Market Segmentation by Type:

Allogeneic Stem Cells Autologous Stem cells

Market Segmentation by Application:

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Table of Contents

Global Canine Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Canine Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Canine Stem Cell Therapy Market Forecast

For more Information, Inquire @:

https://www.a2zmarketresearch.com/enquiry?reportId=21262

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Original post:
Canine Stem Cell Therapy Market to Witness Stunning Growth to Generate Massive Revenue During Forecast 2020 2026 | VETSTEM BIOPHARMA, Cell Therapy...

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs – GlobeNewswire

August 18, 2020 07:00 ET | Source: https://immatics.com/

multilang-release

Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) --

Tuebingen, Germany and Houston, Texas, August 18, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the treatment of the first patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the regulatory body for cell and gene therapies in Germany. In addition, Immatics has been granted regulatory approval by PEI to initiate another phase I clinical trial in Germany to evaluate safety, tolerability and initial signs of clinical efficacy of IMA203.

The clinical trials of the IMA200 series will investigate up to three novel cancer immunotherapies, which include IMA202 (NCT03441100) and IMA203 (NCT03686124). IMA202 and IMA203 are designed to target unique peptides derived from either melanoma-associated antigen 1 (MAGEA1) or preferentially expressed antigen in melanoma (PRAME), respectively. Both are built on Immatics proprietary ACTengine approach in which the patients own T cells are genetically engineered to express an exogenous T cell receptor (TCR) directed against true cancer targets. By introducing this novel cancer specific TCR, the goal is to redirect and selectively activate the patients T cells to fight the tumor. The studies will investigate the safety and tolerability of Immatics Adoptive Cell Therapies (ACT) in patients with target-positive solid cancers and seek initial signals of anti-tumor activity. Moreover, persistence of the infused engineered T cells will be monitored in the patients blood as T cell persistence is considered a major pre-requisite to obtain an anti-tumor response. The aim is to develop innovative personalized immunotherapies targeting a patients tumor selectively and effectively.

The initial group of clinical trial sites in Germany includes the University Hospital Carl Gustav Carus in Dresden, the University Hospital Bonn and the University Hospital of Wrzburg. Previous patients in the IMA200 series were initially enrolled at The University of Texas MD Anderson Cancer Center in Houston, Texas, and more recently at the Columbia University Irving Medical Center in New York and the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania.

Cedrik Britten, MD, Chief Medical Officer of Immatics commented: As part of our strategy to increase the geographical foot-print for our clinical sites, we are currently expanding them in the US and in Europe. We are delighted to have gained a new regulatory approval from PEI and to have treated the first patient in Germany. This expansion elevates our clinical organization to a global level and adds operational flexibility that has become even more important in light of the global COVID-19 pandemic. We look forward to continuing to collaborate with leading clinicians to advance our mission of delivering the power of T cells to cancer patients on both sides of the Atlantic.

Dr. Martin Wermke, Coordinating Investigator and Head of the Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany, commented: Having been involved since the early stages of this clinical research, I am excited to witness the next phase of development of this fascinating pipeline of immunotherapies. I am confident that Immatics innovative T cell therapies hold the potential to alter the future therapeutic landscape of solid and hematologic malignancies.

Additional information about the clinical studies is available at http://www.immatics.com/clinical-programs/ and http://www.clinicaltrials.gov.

About Immatics Adoptive Cell Therapies Adoptive Cell Therapy (ACT) is a therapeutic approach that uses natural or engineered T cells to fight cancer. Immatics has developed three innovative, proprietary approaches to produce Adoptive Cell Therapies: ACTengine, off-the-shelf ACTallo and the multi-target pilot trial ACTolog.

About ACTengine Immatics clinical product class ACTengine is a personalized approach for patients with advanced solid cancers. Patients own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics cancer targets identified by its proprietary XPRESIDENT target discovery platform.

About the ACTengine clinical trials (IMA201, IMA202 and IMA203)

Patient receiving an investigational therapy based on Immatics ACTengine approach.

Notes to Editors

About Immatics Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics pipeline consists of two distinct therapeutic modalities of Adoptive Cell Therapies and TCR Bispecifics. Adoptive Cell Therapy programs are developed in collaboration through Immatics US with The University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). The ACT T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Twitter and LinkedIn.

Forward-Looking Statements: Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Follow this link:
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs - GlobeNewswire

NK Cell Therapy and Stem Cell Therapy Industry Market Structure Analysis for the Period 2026 – The News Brok

The report on NK Cell Therapy and Stem Cell Therapy Industry market added by Market Study Report, LLC, depicts the current & future growth trends of this business besides outlining details pertaining to the myriad geographies that are a part of the regional landscape of NK Cell Therapy and Stem Cell Therapy Industry market. The report further elucidates intricate details regarding the supply and demand analysis, market share, growth statistics and contributions by leading industry players of NK Cell Therapy and Stem Cell Therapy Industry market.

The research report on NK Cell Therapy and Stem Cell Therapy Industry market delivers an exhaustive analysis of this business space while offering significant information pertaining to the factors that are affecting the revenue generation as well as the industry growth. The document also comprises of a detailed assessment of the regional scope of the market alongside its regulatory outlook. Additionally, the report provides with a detailed SWOT analysis while elaborating market driving factors.

Request a sample Report of NK Cell Therapy and Stem Cell Therapy Industry Market at:https://www.marketstudyreport.com/request-a-sample/2707408?utm_source=newsbrok&utm_medium=RV

Additional information including limitations & challenges faced by new entrants and market players in tandem with their respective impact on the revenue generation of the companies is enumerated. The document scrutinizes the impact of COVID-19 pandemic on growth as well as future remuneration of the market.

From the regional perspective of NK Cell Therapy and Stem Cell Therapy Industry market:

Emphasizing on the competitive scenario of the NK Cell Therapy and Stem Cell Therapy Industry market:

Ask for Discount on NK Cell Therapy and Stem Cell Therapy Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2707408?utm_source=newsbrok&utm_medium=RV

Other details specified in the NK Cell Therapy and Stem Cell Therapy Industry market report:

Comprehensive assessment of all opportunities and risks in the NK Cell Therapy and Stem Cell Therapy Industry market.

This exclusive study addresses key questions for stakeholders in the NK Cell Therapy and Stem Cell Therapy Industry Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-nk-cell-therapy-and-stem-cell-therapy-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Phycoerythrin Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-phycoerythrin-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Electronic Emergency Ventilator Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-electronic-emergency-ventilator-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

Continued here:
NK Cell Therapy and Stem Cell Therapy Industry Market Structure Analysis for the Period 2026 - The News Brok

Why Young and Female Patients Don’t Respond as Well to Cancer Immunotherapy – UC San Diego Health

Cancer immunotherapy empowering a patients own immune system to clear away tumors on its own holds great promise for some patients. But for other patients, immunotherapy just doesnt work.

Researchers at University of California San Diego School of Medicine have found evidence that helps explain why patients who are young and/or female have especially low response rates to some types of cancer immunotherapy.

Their findings suggest that since the typically robust immune systems of young and female patients are better at getting rid of tumor cells, the cells left behind are not as readily visible to the immune system to begin with, rendering some types of immunotherapy ineffective.

Due to a process known as immuno-editing, younger and female patients with cancer have cancer-causing genetic mutations that are least visible to the immune system according to a new Nature Communications study by Hannah Carter, PhD, and team at UC San Diego School of Medicine.

The study is published August 17, 2020, in Nature Communications.

Now that we know why some patients dont respond as well to immunotherapy, we can begin developing more informed approaches to treatment decisions for instance, developing predictive algorithms to determine a persons likely response before initiating immunotherapies that may have a high probability of not working or working poorly for them, said senior author Hannah Carter, PhD, associate professor of medicine at UC San Diego School of Medicine.

Cancerous or infected cells wave molecular flags that tell the immune system to clear them away before the problem gets out of control. The flag poles molecules of the Major Histocompatibility Complexes (MHC) are displayed at the surface of most cells in the body. MHCs hold up antigen flags bits of just about everything from inside the cells and display them to immune cell surveyors that are constantly checking for damaged or infected cells. Since tumor cells carry a lot of mutations, they show up frequently among these flags, allowing the immune system to detect and eliminate them.

But some tumor cells evade the immune system by also throwing up a stop sign molecule that keeps the immune system from recognizing the MHC flags. And heres where immune checkpoint inhibitors come in: This type of cancer immunotherapy uses antibodies to make the tumor cell once again visible to the patients immune system.

So why would a persons age or sex influence how well immune checkpoint inhibitors work?

Sex and age differences have long been observed when it comes to immune response. For example, females have twice the antibody response to flu vaccines and are far more susceptible to autoimmune diseases. Similarly, human immune systems tend to weaken as we age. But if females and younger people have stronger immune responses in most cases, you might expect cancer immunotherapy to work better for them, not worse.

To get to the bottom of this conundrum, Carters team looked at genomic information for nearly 10,000 patients with cancer available from the National Institutes of Healths The Cancer Genome Atlas, and another 342 patients with other tumor types available from the International Cancer Genome Consortium database and published studies. They found no age or sex-related differences in MHC function.

What they did find was that, compared to older and male patients with cancer, younger and female patients tend to accumulate more cancer-causing genetic mutations of the sort that MHCs cant present to the immune system as efficiently. Carter said this is likely because robust immune systems of the young and female are better at getting rid of cells displaying well-presented mutant self-antigens, leaving behind tumor cells that rely more heavily on the poorly presented mutations. This selective pressure is known as immuno-editing.

So if a tumor cell doesnt present highly visible, mutated self antigens to begin with, checkpoint inhibitor drugs cant help reveal them to the immune system, she said.

This shows an important thing, that the interplay between the cancer genome and the adaptive arm of the immune system is not a static one, said co-author Maurizio Zanetti, MD, professor of medicine at UC San Diego School of Medicine and head of the Laboratory of Immunology at UC San Diego Moores Cancer Center. Two simple but important variables, age and sex, influence this interplay. The study also emphasizes the master role of the MHC in dictating the outcome of this interplay, reaffirming its central role in the evolution of disease, cancer included, at the level of the individual and population.

Carter cautions that their findings for younger patients dont necessarily apply to children since, genetically speaking, pediatric tumors are very different from adult tumors. In addition, she noted that, like most genomics databases, those used in this study contain data primarily from people of Caucasian descent, and more diversity is needed to confirm that the findings can be generalized to all populations.

Cancer isnt just one disease, and so the way we treat it cant be one-size-fits-all, she said. All checkpoint inhibitors can do is remove the generic block that tumors put up to hide from the immune system. The more we learn about how interactions between tumors and immune systems might vary, the better positioned we are to tailor treatments to each persons situation.

Co-authors of the study also include: Andrea Castro, Rachel Marty Pyke, Xinlian Zhang, Wesley Kurt Thompson, Ludmil B. Alexandrov, Maurizio Zanetti, UC San Diego; and Chi-Ping Day, National Institutes of Health.

The study was funded, in part, by the National Institutes of Health (grants T15LM011271, DP5-OD017937, RO1CA220009, P41GM103504, 5R01CA155010-02, 5R01HL103532-03, 2P50CA101942-11A1, R50RCA211482A, R35CA197633, P01CA168585, 5P50CA168536, GM08042, 1RO1CA155010-02, 5R01HL103532-03, R21CA216772-01A1, T32HL007627, P50CA165962, P01CA163205, K08CA188615), National Science Foundation (graduate fellowship 2015205295), Mark Foundation for Cancer Research (grant 18-022-ELA), CIFAR Fellowship, Blavatnik Family Foundation, Broad Institute SPARC Program, BroadIgnite, BroadNext10, Francis and Adele Kittredge Family Immuno-Oncology and Melanoma Research Fund, Faircloth Family Research Fund, DFCI Center for Cancer Immunotherapy, Leukemia and Lymphoma Society, American Association for Cancer Research, Geoffrey Beene Cancer Research Center, Society for Memorial Sloan Kettering Cancer Center, Lung Cancer Research Foundation, Frederick Adler Chair Fund, One Ball Matt Memorial Golf Tournament, Queen Wilhelmina Cancer Research Award, STARR Foundation, Ludwig Trust, Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant, Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team Translational Research Grant (grant SU2C-AACR-DT17-15), Ben and Catherine Ivy Foundation, Zuckerman STEM Leadership Program, Benoziyo Endowment Fund for the Advancement of Science, DFCI Center for Cancer Immunotherapy Research fellowship, Howard Hughes Medical Institute and American Cancer Society (grant PF-17-042-01LIB).

Disclosure: Co-author Rachel Marty Pyke is an employee and holds stock in Personalis.

View original post here:
Why Young and Female Patients Don't Respond as Well to Cancer Immunotherapy - UC San Diego Health

Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of…

August 17, 2020 02:00 ET | Source: Pluristem Therapeutics, Inc.

HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today its subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC), a specialist healthcare center focused on cell therapy and regenerative medicine. Executives from both companies took part in a signing ceremony held via video conference between Israel and the UAE. The aim of the collaboration is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole. The collaboration between the parties was initiated by the Better Alternatives advisory firm.

The parties have agreed to exchange research results, share samples, join usage of equipment and testing, and other essential activities related to advancing the treatment and research of cell therapies for a broad range of medical conditions, including COVID-19.

ADSCC has been treating COVID-19 patients with stem cells sourced from the patients blood, by returning the cells back into the patients lungs as a fine mist through a nebulizer, a machine that helps a patient breathe in medicine through a mask or mouthpiece. Pluristem has treated patients with its placental PLX-PAD allogenic product via compassionate use programs in Israel and the U.S. and is currently conducting phase II studies in the U.S. and EU.

We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders. We see life science and regenerative medicine as a bridge for building peace, prosperity, and well-being in our region and for the entire world. I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. We are honored to be on the front line of this historical moment, stated Pluristem CEO and President Yaky Yanay.

Dr Yendry Ventura, General Manager of the ADSCC commented, Pluristem is a major player in the cell therapy field with years of experience, a unique platform and a robust clinical pipeline. We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole.

About Abu Dhabi Stem Cells Center Abu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi-based specialist healthcare center focused on cell therapy and regenerative medicine, as well as delivering cutting-edge research on stem cells in the region. The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE. ADSCC specialties include immunology, hematology, clinical stem cell therapy, molecular biology, immunotherapy, orthopedics, and urology amongst others.

About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the aim of the collaboration with the ADSCC is to capitalize on each companys respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole and the belief that it is its obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact:

Dana Rubin Director of Investor Relations 972-74-7107194 danar@pluristem.com

Read more from the original source:
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of...

Brevard Zoo’s Bear ‘Brody’ Received Radiographs and Underwent First Round of Stem-Cell Therapy – SpaceCoastDaily.com

Two injections containing about five million stem cells delivered directly to Brodys hip joints During last months surgery to address an issue with Brodys joints, Dr. Jeffrey Christiansen of Superior Veterinary Surgical Solutions collected a small amount of Brodys fat. (Brevard Zoo image)

BREVARD COUNTY MELBOURNE, FLORIDA During last months surgery to address an issue with Brodys joints, Dr. Jeffrey Christiansen of Superior Veterinary Surgical Solutions collected a small amount of Brodys fat.

A laboratory extracted stem cells from the fat sample, which can be used to reduce pain and inflammation and promote healing of the surgical site.

On Friday morning, Brody was brought back to the L3Harris Animal Care Center to receive his first dose of this medication.

Two injections containing about five million stem cells each were delivered directly to Brodys hip joints. To accomplish this, Dr. Christiansen carefully inserted a needle into Brodys hip and drew a small amount of joint fluid to confirm the tip was in the right place, then administered the injection.

A third, less-concentrated injection was delivered intravenously.

We also captured some radiographs to check on Brodys hip condition.

While we wont be able to evaluate the long-term effectiveness of the surgery for quite some time, he appears to be recovering without complication.

Brody woke from the anesthesia and was returned to his habitat. It is normal for animals to experience discomfort and lameness for a few days following stem-cell injections, but Brody is already back to being his normal, energetic self.

We have enough stem cells banked for an additional 15 doses, which will be administered throughout the course of Brodys life as needed.

Quality veterinary care is expensive. Click here to support animal wellness at the Zoo during this financially challenging time.

CLICK HERE FOR BREVARD COUNTY NEWS

Continued here:
Brevard Zoo's Bear 'Brody' Received Radiographs and Underwent First Round of Stem-Cell Therapy - SpaceCoastDaily.com

Gene targeting helps overcome the resistance of brain cancer to therapy – McGill Newsroom

New insight into a gene that controls energy production in cancer stem cells could help in the search for a more effective treatment for glioblastoma. A McGill-led study published in Nature Communications reveals that suppressing the OSMR gene can improve the effectiveness of radiation therapy.

This approach, led by the laboratory of Arezu Jahani-Asl, Assistant Professor of Medicine at McGill University, was successful in preclinical mouse models where the deletion of the OSMR gene resulted in a significant improvement of tumour response to therapy and expanded lifespan.

Glioblastoma is the most common and aggressive cancerous brain tumour in adults due to its resistance to therapy. Treatment usually involves surgery, followed by chemotherapy and radiation therapy. Despite these intensive efforts, in most cases tumour cells regrow after treatment and the cancer recurs.

Starving cancer stem cells

Glioblastoma tumours contain rare cancer stem cells responsible for therapeutic resistance and tumour regrowth. In the study, researchers uncover the unique role OSMR plays in fortifying cancer stem cells resistance to therapy by strengthening mitochondria, the powerhouse of cell energy production. It makes the long journey to the mitochondria and interacts with energy-producing machineries to force them to generate more energy for cancer cells.

To improve patient response to glioblastoma treatment, we must find new vulnerabilities in cancer stem cells and overcome their resistance to therapy. By suppressing OSMR, we were able to halt energy production in cancer stem cells, essentially starving them to death, says Jahani-Asl.

The study provides evidence that targeting OSMR gene, in combination with radiation therapy, can pave the way for future clinical trials that better treat glioblastoma tumours. The next step is to leverage these tools into a clinical trial, the researchers say.

About the study

OSMR controls glioma stem cell respiration and confers resistance of glioblastoma to ionizing radiation by Ahmad Sharanek, Audrey Burban, Matthew Laaper, Emilie Heckel, Jean-Sebastien Joyal, Vahab D. Soleimani, and Arezu Jahani-Asl is published in Nature Communications. The study was supported by CIHR and The Brain Tumor Charity.

DOI: http://dx.doi.org/10.1038/s41467-020-17885-z

About McGill University

Founded in Montreal, Quebec, in 1821, McGill University is Canadas top ranked medical doctoral university. McGill is consistently ranked as one of the top universities, both nationally and internationally. Itis a world-renownedinstitution of higher learning with research activities spanning two campuses, 11 faculties, 13 professional schools, 300 programs of study and over 40,000 students, including more than 10,200 graduate students. McGill attracts students from over 150 countries around the world, its 12,800 international students making up 31% of the student body. Over half of McGill students claim a first language other than English, including approximately 19% of our students who say French is their mother tongue.

http://www.mcgill.ca/newsroom/ http://twitter.com/McGillU

Read more here:
Gene targeting helps overcome the resistance of brain cancer to therapy - McGill Newsroom

Global Autologous Cell Therapy Market Outlook to 2025 by Therapy, Application, Source, End User and Geography – Yahoo Finance

DUBLIN, Aug. 17, 2020 /PRNewswire/ -- The "Global Autologous Cell Therapy Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Autologous Cell Therapy market is anticipated to grow at a CAGR of 15.9% during the forecast period.

The major factors attributing to the growth of the autologous cell therapy market are the rising incidence of chronic diseases such as autoimmune diseases, cancer, blood disorder, and others.

A rise in the population suffering from chronic diseases is also propelling the demand for market growth. In 2018, as per the AARDA (American Autoimmune Related Diseases Association) statistics, around 50 million Americans have an autoimmune disease, and this number is expected to rise in the future.

As per the CDC (Centers for Disease Control and Prevention) estimates Sickel Cell Disease (SCD) affects around 100,000 Americans annually - and there are few more factors which are playing crucial roles in taking the autologous cell therapy market to the next level, among them one is on-going drug developments for new applications which are expected to further propel the growth of the autologous cell therapy market.

Key Market Trends

Bone Marrow Segment Expected to Hold the Largest Market Share Bone marrow transplant is a technique for replacing damaged and destroyed cells with new stem cells in the bone marrow. Bone marrow is the most commonly used for autologous cell therapy as it can benefit individuals with a range of cancer (malignant) and non-cancer (benign) diseases and will drive the market during the forecast period.

As per the statistics from Globocan 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2% and 7.8%, 5.8%, and 1.4% respectively.

North America Dominates the Market and is Expected to do Same Over the Forecast Period

North America is expected to dominate the overall autologous cell therapy market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cancer, blood disorder, autoimmune diseases, and other diseases and the availability of advanced healthcare infrastructure among the major factors.

In North America, the United States holds the largest market share owing to the factors such as increasing number of population suffering from cancer and other chronic diseases, along with the rising geriatric population and developments related to stem cell therapy and rising demand for biotechnological practices in the country, is anticipated to further drive the demand in this region.

Competitive Landscape

The autologous cell therapy market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and joint ventures with the other companies to consolidate their market positions across the globe.

Some of the companies which are currently dominating the market are Vericel Corporation, Pharmicell Co. Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics Inc., and Opexa Therapeutics.

Key Topics Covered

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Incidence of Chronic Diseases 4.2.2 Emphasis Increasingly on Drug Development for New Applications 4.3 Market Restraints 4.3.1 Systemic Immunological Reactions Possibility 4.3.2 Expensive Practise, Product and High Capital Investment 4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION 5.1 By Therapy 5.1.1 Autologous Stem Cell Therapy 5.1.2 Autologous Cellular Immunotherapies 5.2 By Application 5.2.1 Oncology 5.2.2 Musculoskeletal Disorder 5.2.3 Blood Disorder 5.2.4 Autoimmune Disease 5.2.5 Others 5.3 By Source 5.3.1 Bone Marrow 5.3.2 Epidermis 5.3.3 Others 5.4 By End User 5.4.1 Hospitals 5.4.2 Research Centers 5.4.3 Others 5.5 Geography 5.5.1 North America 5.5.2 Europe 5.5.3 Asia-Pacific 5.5.4 Middle-East and Africa 5.5.5 South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Vericel Corporation 6.1.2 Pharmicell Co. Inc. 6.1.3 Holostem Terapie Avanzate S.r.l. 6.1.4 Lineage Cell Therapeutics, Inc. 6.1.5 Opexa Therapeutics 6.1.6 BrainStorm Cell Therapeutics 6.1.7 Sangamo Therapeutics

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/22argo

Story continues

View post:
Global Autologous Cell Therapy Market Outlook to 2025 by Therapy, Application, Source, End User and Geography - Yahoo Finance